» Articles » PMID: 8532022

Mismatches of Minor Histocompatibility Antigens Between HLA-identical Donors and Recipients and the Development of Graft-versus-host Disease After Bone Marrow Transplantation

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1996 Feb 1
PMID 8532022
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Graft-versus-host disease (GVHD) can be a major complication of allogeneic bone marrow transplantation even when the donor and recipient are siblings and share identical major histocompatibility antigens. The explanation may be a mismatch of minor histocompatibility antigens. We previously characterized five minor histocompatibility antigens, HA-1, 2, 3, 4, and 5, that are recognized by T cells in association with the major histocompatibility antigens HLA-A1 an A2.

Methods: We collected peripheral-blood leukocytes from 148 bone marrow recipients and their sibling donors, who were genotypically HLA identical. Fifty pairs were positive for HLA-A1, 117 were positive for HLA-A2, and 19 were positive for both. The pairs were typed with cytotoxic-T-cell clones specific for minor histocompatibility antigens HA-1, 2, 3, 4, and 5.

Results: Mismatches of HA-3 were equally distributed among recipients in whom GVHD developed and those in whom it did not. By contrast, a mismatch of only HA-1 was significantly correlated with GVHD of grade II or higher (odds ratio, infinity; P = 0.02) in adults. One or more mismatches of HA-1, 2, 4, and 5 were also significantly associated with GVHD (odds ratio, infinity; P = 0.006) in adults. These associations were not observed in children.

Conclusions: A mismatch of minor histocompatibility antigen HA-1 can cause GVHD in adult recipients of allogeneic bone marrow from HLA-identical donors. Prospective HA-1 typing may improve donor selection and identify recipients who are at high risk for GVHD.

Citing Articles

Immune Shielding of Human Heart Valves: A Proof-of-Concept Study of HLA-Targeting Therapy for Transplantations.

Peters M, Zaldumbide A, Groeneveld E, Rabelink M, Peerlings J, van den Bogaerdt A JACC Basic Transl Sci. 2024; 9(11):1345-1359.

PMID: 39619144 PMC: 11604548. DOI: 10.1016/j.jacbts.2024.07.003.


Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation.

Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Diaz-Fernandez P Nat Biotechnol. 2024; .

PMID: 39169264 DOI: 10.1038/s41587-024-02348-3.


Microbiota dictate T cell clonal selection to augment graft-versus-host disease after stem cell transplantation.

Yeh A, Koyama M, Waltner O, Minnie S, Boiko J, Shabaneh T Immunity. 2024; 57(7):1648-1664.e9.

PMID: 38876098 PMC: 11236519. DOI: 10.1016/j.immuni.2024.05.018.


Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome.

Nakamura N, Yamamoto N, Kondo T, Matsumoto M, Ikunari R, Sakai T Int J Hematol. 2024; 119(6):762-767.

PMID: 38523199 DOI: 10.1007/s12185-024-03762-8.


Association Between Human Leukocyte Antigens and Graft-Versus-Host Disease Occurrence in Allogeneic Hematopoietic Stem Cell Transplantation - A 10-Year Experience on Iranian Patients.

Hamidpour M, Roshandel E, Ghaffari Nazari H, Sankanian G, Bonakchi H, Salimi M Arch Iran Med. 2023; 25(12):798-806.

PMID: 37543907 PMC: 10685839. DOI: 10.34172/aim.2022.125.